BNP Paribas Financial Markets Grows Position in Twist Bioscience Corporation $TWST

BNP Paribas Financial Markets raised its holdings in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 242.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 415,609 shares of the company’s stock after purchasing an additional 294,144 shares during the quarter. BNP Paribas Financial Markets’ holdings in Twist Bioscience were worth $13,183,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in TWST. Quarry LP purchased a new stake in Twist Bioscience during the third quarter valued at about $28,000. Smartleaf Asset Management LLC lifted its holdings in Twist Bioscience by 70.6% during the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after purchasing an additional 442 shares during the last quarter. SBI Securities Co. Ltd. lifted its holdings in Twist Bioscience by 68.9% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock valued at $44,000 after purchasing an additional 571 shares during the last quarter. National Bank of Canada FI purchased a new stake in Twist Bioscience during the third quarter valued at about $46,000. Finally, Leonteq Securities AG purchased a new stake in Twist Bioscience during the fourth quarter valued at about $48,000.

Twist Bioscience Price Performance

TWST stock opened at $69.22 on Monday. The company has a current ratio of 2.70, a quick ratio of 2.42 and a debt-to-equity ratio of 0.03. The company’s 50 day moving average is $57.14 and its 200 day moving average is $46.01. The stock has a market cap of $4.31 billion, a price-to-earnings ratio of -52.04 and a beta of 2.23. Twist Bioscience Corporation has a 1-year low of $23.30 and a 1-year high of $80.50.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.22). The company had revenue of $110.72 million during the quarter, compared to the consensus estimate of $107.64 million. Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The firm’s revenue for the quarter was up 19.3% on a year-over-year basis. During the same quarter last year, the company posted ($0.66) earnings per share. Sell-side analysts predict that Twist Bioscience Corporation will post -1.99 EPS for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, Director Robert Chess sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $47.00, for a total transaction of $470,000.00. Following the transaction, the director directly owned 21,084 shares in the company, valued at $990,948. This trade represents a 32.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jan Johannessen sold 12,000 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $56.12, for a total transaction of $673,440.00. Following the transaction, the director owned 17,754 shares in the company, valued at $996,354.48. The trade was a 40.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 42,768 shares of company stock valued at $2,390,888. 3.08% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Barclays upped their price objective on shares of Twist Bioscience from $55.00 to $65.00 and gave the company an “overweight” rating in a report on Monday, May 4th. Leerink Partners set a $80.00 price target on shares of Twist Bioscience in a report on Friday, May 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a report on Friday, March 27th. Guggenheim increased their price target on shares of Twist Bioscience from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Finally, Robert W. Baird increased their price target on shares of Twist Bioscience from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Tuesday, May 5th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $58.00.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.